Video
Expanding Options for Emerging Biopharma in the U.S.: A conversation with Meg Hooton, IQVIA Biotech
Mar 13, 2026

This conversation between Murray Aitken of the IQVIA Institute for Human Data Science and Meg Hooton of IQVIA Biotech offers a candid, data-grounded perspective on the pressures and opportunities facing emerging biotech companies today.

They explore trends in clinical trial activity, shifts in development productivity, the realities of new drug launches, evolving commercialization models, capital constraints, and what it will take for emerging biopharma to sustain innovation in an increasingly complex market environment.

Related solutions

Contact Us